

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.427D3APPLICATION NO.  
10/010,940 #141

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCKET NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,786,148	07/28/98	Bandman et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	DE 19649207	11/27/96	Germany		X
	AC	EP 317 141 A2	05/24/89	EPO		
	AD	EP 652 014 A1	5/10/95	EPO		
	AE	EP 936 270 A2	08/18/99	EPO		X
	AF	WO 93/14755	08/05/93	PCT		
	AG	WO 93/25224	12/23/93	PCT		
	AH	WO 94/09820	05/11/94	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
AJ	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
AK	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
AL	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
AM	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.
AN	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
AO	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.

EXAMINER

DATE CONSIDERED

9/6/04

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

ATTY. DOCKET NO.  
210121.427D3APPLICATION NO..  
10/010,940

## INFORMATION DISCLOSURE STATEMENT

(Use separate sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER (Patent & Trademark Office)	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	--	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
A	BA	WO 95/04548	02/16/95	PCT		
	BB	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
A	BC	WO 95/30758	11/16/95	PCT		
	BD	WO 96/21671	07/18/96	PCT		
	BE	WO 97/33909	09/18/97	PCT		
	BF	WO 98/12302	03/26/98	PCT		
	BG	WO 98/17687	04/30/98	PCT		
A	BH	WO 98/20117	05/14/98	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A	BI	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
	BJ	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
	BK	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."
	BL	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
	BM	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
	BN	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
A	BO	El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

## INFORMATION DISCLOSURE STATEMENT

(See several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOC. #	NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	--------	--------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
CA		WO 98/31799	07/23/98	PCT		
CB		WO 98/37039	08/27/98	PCT		X
CC		WO 98/37093	08/27/98	PCT		
CD		WO 98/37418	08/27/98	PCT		
CE		WO 98/38310	09/03/98	PCT		
CF		WO 98/39446	09/11/98	PCT		
CG		WO 98/45435	10/15/98	PCT		
CH		WO 98/50567	11/12/98	PCT		
CI		Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.				
CJ		GenBank Accession Number AF047020, February 1, 1999.				
CK		Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 $\alpha$ in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.				
CL		Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.				
CM		Hillier et al., Genbank Accession No. AA100799, December 23, 1997.				
CN		Hillier et al., Genbank Accession No. R20590, April 18, 1995.				
CO		Hudson, T., Genbank Accession No. G22461, May 31, 1996.				

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
DA		WO 99/06548	02/11/99	PCT		
DB		WO 99/06552	02/11/99	PCT		
DC		WO 99/06550	02/11/99	PCT		
DD		WO 99/25825	05/27/99	PCT		
DE		WO 99/31236	06/24/99	PCT		
DF						
DG						

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DH		Kroger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
DI		Lalvani et al., "Rapid effector function in CD8 <sup>+</sup> memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.
DJ		National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
DK		National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
DL		National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.
DM		National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.
DN		Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						
EB						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
EC					
ED					
EE					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EF	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.
EG	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.
EH	Schmidt-Wolf et al., "Activated T cells and cytokine-induced CD3 <sup>+</sup> CD56 <sup>+</sup> killer cells," <i>Annals of Hematology</i> 74:51-56, 1997.
EI	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.
EJ	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
EK	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
EL	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631Sheet 6 of 7  
RECEIVED  
JAN 14 2003  
TECH CENTER 160012900

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						
FB						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FC					
FD					
FE					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FF	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
FG	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
FH	Van Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.
FI	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
FJ	Yee et al., "Isolation of tyrosinase-specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
FK	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.
FL	
FM	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 5, 2001GROUP ART UNIT  
1631

Sheet 7 of 7

RECEIVED  
JAN 14 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
CA	GC	WO 00/04149	1/27/00	WIPO		
I	GD	WO 01/25272	4/12/01	WIPO		
	GE	WO 01/34802	5/17/01	WIPO		
A	GF	WO 01/51633	7/19/01	WIPO		
	GG					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


	GH	
	GI	
	GK	
	GL	
	GM	
	GN	
	GO	

EXAMINER

DATE CONSIDERED

9/6/04

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-99)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427D3	APPLICATION NO. 10/010,940
 <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Jiangchun Xu et al.	
		FILING DATE December 5, 2001	GROUP ART UNIT 1631



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Aspinall, J.O. et al., "Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues," <i>Journal of Urology</i> 154: 622-628, August 1996.
	AQ	Fannon, M.R., "Gene expression in normal and disease states – identification of therapeutic targets," <i>Trends in Biotechnology</i> 14: 294-298, August 1996.
	AR	Garde, S.V. et al., "Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)," <i>Cancer Letters</i> 78: 11-17, 1994.
		GenBank Database, Accession No. AA112574, May 29, 2003.
		Murphy, G. et al., "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients," <i>Anticancer Research</i> 15: 1473-1480, 1995.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).